Personal information

No personal information available

Activities

Employment (1)

Experimental Pharmacology and Oncology Berlin-Buch GmbH: Berlin, DE

2009-01-01 to 2031-01-01
Employment
Source: Self-asserted source
Jens Hoffmann

Education and qualifications (1)

Humboldt University: Berlin, DE

Education
Source: Self-asserted source
Jens Hoffmann

Works (50 of 70)

Items per page:
Page 1 of 2

Prädiktive Testung von Tumorgewebe und ihre klinischen Konsequenzen

Springer Reference Medizin
2022 | Book chapter
Part of ISBN: 9783662467640
Part of ISBN: 9783662467640
Part of ISSN: 2625-3461
Part of ISSN: 2625-350X
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann

A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies.

Frontiers in oncology
2022-06-21 | Journal article
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann

Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker.

British journal of cancer
2022-05-21 | Journal article
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Breaking the crosstalk of the Cellular Tumorigenic Network by low-dose combination therapy in lung cancer patient-derived xenografts

Communications Biology
2022-01-17 | Journal article
Contributors: Dennis Gürgen; Theresia Conrad; Michael Becker; Susanne Sebens; Christoph Röcken; Jens Hoffmann; Stefan Langhammer
Source: check_circle
Crossref

Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma

International journal of cancer
2021 | Journal article
Part of ISSN: 0020-7136
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 3)‎

Mutation-specific effects of NRAS oncogenes in colorectal cancer cells

Advances in biological regulation
2021 | Journal article
Part of ISSN: 2212-4926
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine

Neoplasia (New York, N.Y.)
2021 | Journal article
Part of ISSN: 1522-8002
Source: Self-asserted source
Jens Hoffmann

Patient-Derived Xenografts from Solid Tumors (PDX) for Models of Metastasis

Methods in molecular biology (Clifton, N.J.)
2021 | Journal article
Part of ISSN: 1064-3745
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data.

Cancers
2021-11-30 | Journal article
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 4)‎

Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models.

Molecular cancer
2021-10-21 | Journal article
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer

Oncotarget
2020 | Journal article
Part of ISSN: 1949-2553
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Hormone Replacement Therapy and Cancer

CRC Press
2020-07-26 | Book
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann

Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures

PLoS genetics
2019 | Journal article
Part of ISSN: 1553-7390
Source: Self-asserted source
Jens Hoffmann

RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance

PloS one
2019 | Journal article
Part of ISSN: 1932-6203
Source: Self-asserted source
Jens Hoffmann

A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers

International journal of cancer
2018 | Journal article
Part of ISSN: 0020-7136
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Editorial: Cancer Models

Frontiers in oncology
2018 | Journal article
Part of ISSN: 2234-943X
Source: Self-asserted source
Jens Hoffmann

Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression

European journal of cancer (Oxford, England : 1990)
2018 | Journal article
Part of ISSN: 0959-8049
Source: Self-asserted source
Jens Hoffmann

Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas

Journal of cancer research and clinical oncology
2018 | Journal article
Part of ISSN: 0171-5216
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Animal models for personalized treatment options

International journal of clinical pharmacology and therapeutics
2017 | Journal article
Part of ISSN: 0946-1965
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 3)‎

Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer

International journal of cancer
2017 | Journal article
Part of ISSN: 0020-7136
Source: Self-asserted source
Jens Hoffmann

Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain

Scientific reports
2017 | Journal article
Part of ISSN: 2045-2322
Source: Self-asserted source
Jens Hoffmann

Choosing wisely - Preclinical test models in the era of precision medicine

Cancer treatment reviews
2017 | Journal article
Part of ISSN: 0305-7372
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer

Oncotarget
2017 | Journal article
Part of ISSN: 1949-2553
Source: Self-asserted source
Jens Hoffmann

Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors

Nature communications
2017 | Journal article
Part of ISSN: 2041-1723
Source: Self-asserted source
Jens Hoffmann

Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6

Oncotarget
2017 | Journal article
Part of ISSN: 1949-2553
Source: Self-asserted source
Jens Hoffmann

Predictive In Vivo Models for Oncology

Handbook of experimental pharmacology
2016 | Journal article
Part of ISSN: 0171-2004
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.

Targeted oncology
2016-08-01 | Journal article
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option

International journal of cancer
2015 | Journal article
Part of ISSN: 0020-7136
Source: Self-asserted source
Jens Hoffmann

Integrative oncology drug discovery accompanied by preclinical translational research as prerequisite for clinical development

Chinese clinical oncology
2014 | Journal article
Part of ISSN: 2304-3865
Source: Self-asserted source
Jens Hoffmann

Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack

Biotechnology journal
2014 | Journal article
Part of ISSN: 1860-6768
Source: Self-asserted source
Jens Hoffmann

Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer

International journal of cancer
2014 | Journal article
Part of ISSN: 0020-7136
Source: Self-asserted source
Jens Hoffmann

Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics

Genome Medicine
2014-10 | Journal article
Part of ISSN: 1756-994X
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann

Mutation Status of KRAS, BRAF, PIK3CA and Expression Level of AREG and EREG Identify Responders to Cetuximab in a Large Panel of Patient Derived Colorectal Carcinoma Xenografts of All Four UICC Stages

Journal of Cancer Therapy
2013 | Journal article
Part of ISSN: 2151-1934
Part of ISSN: 2151-1942
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann

Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines

Frontiers in oncology
2011 | Journal article
Part of ISSN: 2234-943X
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells

PloS one
2011 | Journal article
Part of ISSN: 1932-6203
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer

Clinical cancer research : an official journal of the American Association for Cancer Research
2010 | Journal article
Part of ISSN: 1078-0432
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

In vitro characterization of ZK 230211--A type III progesterone receptor antagonist with enhanced antiproliferative properties

The Journal of steroid biochemistry and molecular biology
2010 | Journal article
Part of ISSN: 0960-0760
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 3)‎

Polymeric micelles for parenteral delivery of sagopilone: physicochemical characterization, novel formulation approaches and their toxicity assessment in vitro as well as in vivo

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
2010 | Journal article
Part of ISSN: 0939-6411
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 3)‎

Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets

Genome medicine
2010 | Journal article
Part of ISSN: 1756-994X
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

The antiprogestin Lonaprisan inhibits breast cancer cell proliferation by inducing p21 expression.

Molecular and cellular endocrinology
2010-12-05 | Journal article
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann

Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases

Neuro-oncology
2009 | Journal article
Part of ISSN: 1522-8517
Source: Self-asserted source
Jens Hoffmann

Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption

Clinical cancer research : an official journal of the American Association for Cancer Research
2009 | Journal article
Part of ISSN: 1078-0432
Source: Self-asserted source
Jens Hoffmann

Aranciamycin analogs generated by combinatorial biosynthesis show improved antitumor activity

Applied microbiology and biotechnology
2008 | Journal article
Part of ISSN: 0175-7598
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers

Clinical cancer research : an official journal of the American Association for Cancer Research
2008 | Journal article
Part of ISSN: 1078-0432
Source: Self-asserted source
Jens Hoffmann

Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone

Cancer research
2008 | Journal article
Part of ISSN: 0008-5472
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Investigational developments for the treatment of progesterone-dependent diseases

Expert opinion on investigational drugs
2008 | Journal article
Part of ISSN: 1354-3784
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 3)‎

Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate

Expert opinion on investigational drugs
2008 | Journal article
Part of ISSN: 1354-3784
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 3)‎

Cloning and heterologous expression of the aranciamycin biosynthetic gene cluster revealed a new flexible glycosyltransferase

Chembiochem : a European journal of chemical biology
2007 | Journal article
Part of ISSN: 1439-4227
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer

Topics in Medicinal Chemistry
2006 | Book chapter
Part of ISBN: 9783540331193
Part of ISBN: 9783540331209
Part of ISSN: 1862-2461
Part of ISSN: 1862-247X
Contributors: Jens Hoffmann
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎

Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development

Angewandte Chemie (International ed. in English)
2006 | Journal article
Part of ISSN: 1433-7851
Source: Self-asserted source
Jens Hoffmann
grade
Preferred source (of 2)‎
Items per page:
Page 1 of 2